

PRESS RELEASE

10 February 2022 11:50:00 CET

Expert speaks about importance of monitoring neuromuscular blockade, in a newly released podcast by patient safety organisation

News: Uppsala, on February 10, 2022. Senzime today announces the release of a Podcast by the patient safety organization (APSF), highlighting the importance of monitoring neuromuscular blockade being just as important as monitoring blood pressure, oxygenation, and ventilation during anesthesia care.

The podcast is the first out of two podcasts on this topic issued by the Anesthesia Safety Patient Foundation. Due to the importance of monitoring, having access to a reliable monitor is crucial. The first episode covers three different technologies, Peripheral Nerve Stimulator (PNS), Mechanomyography (MMG) and acceleromyography (AMG). The second podcast will include Electromyography (EMG), TetraGraphs technology base.

The clinician in the podcast concluded that PNS technology is unable to provide accurate train of four monitoring. The use of the peripheral nerve stimulator to monitor neuromuscular blockade may lead to about 35% of patients with residual weakness. MMG on the other hand is the historic gold standard but clinically unpractical, more used as a comparison for newer technologies.

The widely used AMG devices suffer from certain issues, like the inability to use it when the arm is tucked during surgical procedures and the need to normalize values before administering blocking agents to avoid overestimating return of intact neuromuscular function. Patient movement when waking up from anesthesia can also lead to unreliable measurements.

According to the podcast barriers to routine use of quantitative neuromuscular monitoring may include lack of knowledge, overconfidence, inconsistent training, and lack of easy access to and easy to use reliable quantitative neuromuscular monitors.

Pia Renaudin, CEO of Senzime, says: *“All initiatives to spread awareness around these preventable complications are a great leap towards making quantitative monitoring clinical practice in all hospitals.”*

About the podcast

The Anesthesia Safety Patient Foundations mission is to improve the safety of patients during anesthesia care

[Link to the podcast](#)

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Sensime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Sensime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm's main market (ticker SEZI) since June, 30 2021. www.senzime.com

Attachments

[Expert speaks about importance of monitoring neuromuscular blockade, in a newly released podcast by patient safety organisation](#)